News-Medical.Net on MSN
New evidence shows hematopoietic cell transplantation offers durable relief for sickle cell disease
Patients who underwent hematopoietic cell transplantation for sickle cell disease saw high rates of survival without disease ...
2don MSN
Long-term outlook is positive for most after hematopoietic cell transplant for sickle cell disease
Patients who underwent hematopoietic cell transplantation for sickle cell disease saw high rates of survival without disease ...
Cellarity, a clinical-stage biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today announced the presentation of new preclinical data on ...
Cambridge-based Fulcrum Therapeutics said it will aim to launch a large clinical trial in the second half of 2026 to prove ...
LONDON--(BUSINESS WIRE)--MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, today presented new pre-clinical data for its lead RNA activation program for the treatment ...
SHANGHAI, Aug. 26, 2025 /PRNewswire/ -- CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the ...
Painful symptoms of sickle-cell disease begin within the first year of life. Hydroxyurea (hydroxycarbamide) has been shown to reduce pain in adults (N Engl J Med. 1995;332:1317-1322) and has been ...
Five studies presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition reveal new ...
A study assessing the real-world commercial roll-out of gene therapies for sickle cell disease and beta thalassemia offers ...
SHANGHAI, Aug. 26, 2025 /PRNewswire/ -- CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback